medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2017, Number 1

<< Back Next >>

Acta Med 2017; 15 (1)

Response to the oncospecific treatment in non-microcytic carcinomas in non-surgical stage IIIA

Díaz GD, León VYJ, Fernández GS, Díaz TM, Sánchez OR, Osés HL

Language: Spanish
References: 19
Page: 20-24
PDF size: 145.31 Kb.


ABSTRACT

Non-small-cell lung cancer includes the most frequent malignant tumors of the lung. A descriptive, ambispective study was carried out to evaluate the clinical and radiological evolution of 61 patients with non-surgical stage IIIA non-small-cell lung cancer, treated with polychemotherapy and/or radiotherapy in the Hospital Benéfico Jurídico in the period between January 2011 and December 2013. Male subjects (70.5%) 60 years and older (63.9%) prevailed. Oncospecific treatment significantly reduced weight loss (52.5% vs. 13.1%, p = 0.007), thoracic pain (55.7% vs. 27.9%, p = 0.015) and expectoration (31.1% vs. 18.0%, p = 0.043). After the oncospecific treatment, a progressive worsening of the functional status was found (p = 0.015). More than half of the patients (57.4%) were stable (27.8%) or with some objective antitumor response (29.6%). Nevertheless, 42.6% were in progression of the disease. Although non-surgical oncospecific treatment results in a significant improvement of some symptoms in patients with stage IIIA non-small-cell lung cancer, their functional status worsens progressively, with a low objective antitumor response.


REFERENCES

  1. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison’s Principles of Internal Medicine. [book in CD ROOM]. 18 ed. New York: McGraw-Hill Companies, Inc.; 2012.

  2. NCCN. Non-small cell lung cancer. [citado Mar 2012]. Disponible en: http://nccn.com/guidelines/nsclc

  3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.

  4. Rodríguez CA, Martín RA, Hernández CK. Concordancia clínica, tomográfica y anatomopatológica en el cáncer de pulmón. MEDISAN. 2011; 15 (5): 650-656.

  5. Amorín Kajatt E. Cáncer de pulmón, una revisión sobre el conocimiento actual, métodos diagnósticos y perspectivas terapéuticas. Rev Peru Med Exp Salud Publica. 2013; 30: 85-92.

  6. Rami R. Nueva clasificación TNM del cáncer de pulmón. Arch Bronconeumol. 2009; 45: 159-161.

  7. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009; 136: 260-271.

  8. Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgemsztern D et al. Thoroughness of mediastinal staging in stage IIIA non-small cell lung cancer. J Thorac Oncol. 2012; 7: 188-195.

  9. Fuente Alonso C de la, Regueiro C, Cajón E, Varcárcel F, García Menocal MI, López-García Gallo C et al. Comparación radio quimioterapia concomitante con Taxol y Vincristina en el carcinoma de pulmón no microcítico localmente avanzado. Arch Bronconeumol. 2008; 40: 1-151.

  10. Alonso MR, Sayas CJ, García LR, Coronado PM, Monsó ME, López EA. Utilidad de la tomografía por emisión de positrones en la detección de metástasis ocultas extratorácicas en el carcinoma broncogénico no células pequeñas. Arch Bronconeumol. 2010; 46: 238-243.

  11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2007; 346: 92-98.

  12. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012; 30: 3084-3092.

  13. Castro Carpeño J, Belda Iniesta C, Gonzáles Barón M. Carcinoma no microcítico de pulmón: aspectos generales. En: Cortés Funes H, Colomer Bosch R. Tratado de oncología. Segunda edición. Barcelona: Publicaciones Permanyer. 2009.

  14. Sánchez De Cos Escuín J. El cáncer de pulmón en España, epidemiología supervivencia y tratamiento actuales. Arch Bronconeumol. 2009; 45: 341-8.

  15. Montero C, Rosales M, Otero I, Blanco M, Rodríguez G, Peterga S, y cols. Cáncer de pulmón en el área sanitaria de la Coruña: incidencia, abordaje clínico y supervivencia. Arch Bronconeumol. 2008; 39: 209-16.

  16. NICE clinical guideline 121. Lung cancer: the diagnosis and treatment of lung cancer [citado Abr 2011] [42 pantallas]. Disponible en: http://www.nice.org.uk/ guidance/CG121

  17. Edge SB, Byrd DR, Compton CC et al. eds. AJCC Cancer Staging Manual. 7th Ed. Nueva York, NY: Springer; 2010.

  18. Bunn P: Translation of the biology of lung cancer to targeted therapies. Educational Book. ASCO 2009. 31 Annual Meeting; 2007, Mayo 12 – 15; San Francisco; 395, 406

  19. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian A, et al. Treatment of Stage III Non-small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013; 144: 1743.




2020     |     www.medigraphic.com